Entry Point Capital, LLC Amicus Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding FOLD
# of Institutions
285Shares Held
321MCall Options Held
260KPut Options Held
261K-
Vanguard Group Inc Valley Forge, PA28.6MShares$314 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY28.1MShares$308 Million8.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY27.4MShares$301 Million3.71% of portfolio
-
Black Rock Inc. New York, NY24.4MShares$268 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA21.1MShares$232 Million0.04% of portfolio
About AMICUS THERAPEUTICS, INC.
- Ticker FOLD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 280,497,984
- Market Cap $3.08B
- Description
- Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...